The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
|Videos|July 20, 2011
Karen Hagemaster on Chemo Documentation Study
Author(s)Karen Hagemaster, RN, BSN
Karen Hagemaster from Advocate Good Samaritan Hospital on Chemotherapy Documentation Study
Advertisement
Karen Hagemaster, RN, BSN, Oncology Services at Advocate Good Samaritan Hospital Talks About the Chemotherapy Documentation Study she was involved in that focused on a verification process for the safe administration of chemotherapy and compliance with hospital policy and regulatory guidelines.
Advertisement
Related to this article
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
3
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
4
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
5